Suven Life Sciences, a clinical-stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, announced today scientific presentation at the upcoming 76th American Academy of Neurology (AAN) annual meeting being held April 13-18, 2024, in Denver, USA and virtually.

The AAN Annual Meeting is the world's largest gathering of neurologists and neuroscience professionals and offers top-tier education and the latest in scientific discoveries, clinical updates, and many more from around the globe.

Suven's scientific presentation at AAN will highlight details of the positive study results from its Phase-2 proof-of-concept study assessing the safety and efficacy of samelisant for the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. The study met primary endpoint, with samelisant demonstrating statistically significant and clinically meaningful reduction in EDS measured by the Epworth Sleepiness Scale (ESS) total score compared to placebo at Day 14 (p<0.05). Highly statistically significant effects were observed against placebo for the other efficacy endpoints related to EDS like Clinical Global Impression of Severity (CGI-S) score, Patient Global Impression-Change (PGIC), and Clinical Global Impression of Change (CGI-C).